title: Topical Application of Green Tea Polyphenol (-)-Epigallocatechin-3-gallate (EGCG) for Prevention of Recurrent Oral Neoplastic Lesions.
abstract: A preliminary study was conducted to investigate feasibility of using an oral cancer chemopreventive agent (-)-epigallocatechin-3-gallate (EGCG), the most biologically active component in the green tea extract, in a form of 'swish-and-spit' mouthwash. Such application of EGCG is beneficial as it maximizes exposure of the oral mucosa to the agent but minimizes systemic side effect.
  
  
  
  The study was conducted on individuals suspected to have oral field cancerization who are at a high risk for developing recurrent oral precancerous and carcinomatous lesions. EGCG was used as a daily mouthwash for 7 days. EGCG's ability to modulate target molecules implicated in oral carcinogenesis was assessed by measuring the change in expression level of biomarkers.
  
  
  
  Immunohistochemical expression of phosphoactivated epidermal growth factor receptor (pEGFR), cyclooxygenase-2 (cox-2) and ki-67 were evaluated at baseline and at the endpoint (day 8). Although not statistically significant, overall decrease in expression levels of pEGFR (27.5%), cox-2 (15.9%) and ki-67 positive cells (51.8%) were observed following EGCG treatment. Moreover, a detectable level of EGCG was found in saliva but not in plasma after the one-week treatment regime, demonstrating local availability of EGCG in oral mucosa without significant systemic absorption.
  
  
  
  To best of our knowledge this is the first study to explore use of oral cancer chemopreventive agent in a form of mouthwash in patients with oral field cancerization. Although a definitive conclusion was not reached due to limited sample size, if proven effective, EGCG therapy may offer a non-invasive preventive modality for oral field cancerization.
authors.affiliation: Division of Oral and Maxillofacial Pathology, Columbia University College of Dental Medicine, New York.
authors.forename: Angela J
authors.initials: AJ
authors.lastname: Yoon
authors.forename: Jing
authors.initials: J
authors.lastname: Shen
authors.forename: Regina M
authors.initials: RM
authors.lastname: Santella
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Philipone
authors.forename: Hui-Chen
authors.initials: HC
authors.lastname: Wu
authors.forename: Sidney B
authors.initials: SB
authors.lastname: Eisig
authors.forename: Andrew
authors.initials: A
authors.lastname: Blitzer
authors.forename: Lanny G
authors.initials: LG
authors.lastname: Close
authors.forename: David J
authors.initials: DJ
authors.lastname: Zegarelli
keywords: (−)-epigallocatechin-3-gallate; feasibility trial; oral field cancerization; topical chemopreventive agent